Literature DB >> 24219331

Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-κB signalling.

Valerie Pede1, Ans Rombout, Jolien Vermeire, Evelien Naessens, Hanne Vanderstraeten, Jan Philippé, Bruno Verhasselt.   

Abstract

Chronic lymphocytic leukaemia (CLL) is a disease with a highly variable prognosis. The clinical course can however be predicted thanks to prognostic markers. Poor prognosis is associated with expression of a B cell receptor (BCR) from unmutated immunoglobulin variable heavy-chain genes (IGHV) and expression of zeta-associated protein of 70 kDa (ZAP70). The reason why ZAP70 expression is associated with poor prognosis and whether the protein has a direct pathogenic function is at present unknown. By transfer of ZAP70 to CLL cells, we show here that expression of ZAP70 in CLL cells leads to increased expression of the nuclear factor (NF)-κB target genes interleukin-1β (IL1B), IL6 and IL8 upon BCR triggering. This could be blocked by inhibition of NF-κB signalling through inhibition of IκB kinases (IKK). Transcriptome analysis identified a NF-κB RELA signature imposed by ZAP70 expression in BCR-stimulated CLL cells. We conclude that ZAP70 acts directly as an amplifier of NF-κB signalling in CLL cells which could be an underlying mechanism for its association with poor prognosis and which may represent a therapeutic target.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell receptor; chronic lymphocytic leukaemia; nuclear factor-κB; zeta-associated protein of 70

Mesh:

Substances:

Year:  2013        PMID: 24219331     DOI: 10.1111/bjh.12588

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation.

Authors:  Sarah C Roode; Daniel Rotroff; Anne C Avery; Steven E Suter; Dorothee Bienzle; Joshua D Schiffman; Alison Motsinger-Reif; Matthew Breen
Journal:  Chromosome Res       Date:  2015-06-03       Impact factor: 5.239

2.  Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia.

Authors:  Gonzalo Blanco; Anna Puiggros; Barbara Sherry; Lara Nonell; Xavier Calvo; Eulàlia Puigdecanet; Pui Yan Chiu; Yasmine Kieso; Gerardo Ferrer; Florencia Palacios; Magdalena Arnal; María Rodríguez-Rivera; Eva Gimeno; Eugènia Abella; Kanti R Rai; Pau Abrisqueta; Francesc Bosch; Alexandre Calon; Ana Ferrer; Nicholas Chiorazzi; Blanca Espinet
Journal:  Exp Hematol       Date:  2021-01-07       Impact factor: 3.249

3.  Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells.

Authors:  Qingwei Kang; Shu Yan
Journal:  Exp Ther Med       Date:  2015-02-03       Impact factor: 2.447

4.  B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.

Authors:  Fei Fei; Eun Ji Joo; Somayeh S Tarighat; Isabelle Schiffer; Helicia Paz; Muller Fabbri; Hisham Abdel-Azim; John Groffen; Nora Heisterkamp
Journal:  Oncotarget       Date:  2015-05-10

Review 5.  Targeting Bruton's tyrosine kinase in B cell malignancies.

Authors:  Rudi W Hendriks; Saravanan Yuvaraj; Laurens P Kil
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

Review 6.  Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types?

Authors:  Joseph R Slupsky
Journal:  Scientifica (Cairo)       Date:  2014-07-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.